I attended the 2017 Canadian Agency for Drugs and Technologies in Health Symposium on April 24 and 25, and had the opportunity to present some new research on patient and public engagement in Canadian drug assessment. This research examines participants’ ideas about the goals, strengths and challenges of public and patient engagement in Ontario’s CED and CADTH’s CDR processes. It compares the views of current committee members, agency officials, and patient groups to the views expressed by members of these groups in consultancy reports and parliamentary committees shortly after public and patient engagement processes were initiated, in 2006 and 2010. The presentation is available here. A revised version presented at the Canadian Political Science Association Meeting in Toronto on June 1 is available here. The research will be submitted for peer review and publication this summer, and updates will be posted on this website.